Clinical Trial Update: Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas [Phase 1]

View source ↗

Summary

Phase 1 safety and efficacy study of a dendritic cell (DC) vaccine for recurrent or progressive high-grade gliomas (WHO grade III and IV) in Beijing Tiantan Hos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma

Drugs mentioned

• DC Vaccine

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: WHO Grade III Gliomas, WHO Grade IV Gliomas | Phase 1 | Status: RECRUITING